Investor Updates

18. December 2006
Combination of Herceptin and Avastin shows promise in treatment of aggressive form of breast cancer
more

15. December 2006
Herceptin provides proven survival benefit in advanced breast cancer and the best chance of a cure in early breast cancer
more

15. December 2006
Tarceva receives positive EU opinion for the treatment of metastatic pancreatic cancer
more

15. December 2006
Roche offers the FDA additional Mircera data
more

14. December 2006
Landmark study of Avastin in lung cancer published today in New England Journal of Medicine
more

13. December 2006
Changes to the Roche Board of Directors and executive management
more

12. December 2006
MabThera dramatically improves survival for first-line Non-Hodgkin Lymphoma patients
more

12. December 2006
Avastin shows positive outcomes in patients with advanced kidney cancer
more

11. December 2006
Xeloda meets primary endpoint in multinational Phase III advanced colorectal cancer study
more

06. December 2006
Halozyme and Roche enter agreement for the application of Enhanze, a novel technology to improve drug delivery
more

05. December 2006
New nanomechanical method for detecting disease- and treatment-relevant genes
more

04. December 2006
Employees support children affected by HIV/AIDS at the Annual Roche AIDS Walk
more

30. November 2006
Herceptin filed for additional indication of early-stage HER2-positive breast cancer in Japan
more

20. November 2006
NeoRecormon receives positive opinion in Europe for convenient once weekly treatment of anaemia in cancer patients with solid tumours
more

20. November 2006
Mircera - first drug to correct anaemia in all chronic kidney disease patients with a simple twice-monthly dosing schedule
more

17. November 2006
FDA approves Herceptin for the adjuvant treatment of HER2-positive node-positive breast cancer
more

27. October 2006
Customising treatment with Pegasys plus Copegus improves chances for cure in Hepatitis C
more

27. October 2006
Roche´s oral polymerase inhibitor shows strong antiviral activity in chronic hepatitis C patients
more

20. October 2006
Science Magazine ranks Roche No. 3 among Top Employers in the Biotech and Pharmaceutical Industries
more

17. October 2006
Roche´s nine-month sales hit record high
more

17. October 2006
Roche and InterMune sign agreement to collaborate on the research, development and commercialization of Hepatitis C Protease Inhibitors
more

16. October 2006
Seven abstracts on innovative anaemia drug MIRCERA accepted for presentation at the American Society of Nephrology Annual Meeting
more

16. October 2006
Reminder: Roche´s Third Quarter Sales 2006 Release
more

13. October 2006
Roche progresses its oral polymerase inhibitor into phase II development study in patients with hepatitis C
more

13. October 2006
Roche files Herceptin plus hormonal therapy for advanced HER2-positive breast cancer with European Authorities
more

12. October 2006
Roche Diagnostics announces launch of Accu-Chek Spirit insulin pump system
more

12. October 2006
UNICEF and Roche announce partnership to improve the lives of children orphaned by AIDS in Africa
more

12. October 2006
Avastin approved in US for first-line treatment of most common form of lung cancer
more

09. October 2006
U.S. regulatory authority lifts import alert for Accu-Chek Spirit insulin pump system
more

05. October 2006
Fuzeon combined with new investigational HIV drug results in remarkably high number of HIV patients achieving undetectable viral load
more

05. October 2006
Plexxikon and Roche enter partnership to develop targeted cancer therapeutic medicine PLX4032
more

02. October 2006
Avastin and Xeloda set new standards for the treatment of first line metastatic colorectal cancer
more

02. October 2006
Herceptin added to hormonal therapy increases progression-free survival in patients with advanced HER2-positive breast cancer
more

02. October 2006
Tamiflu significantly reduces the risk of death from influenza
more

19. September 2006
Roche´s Third Quarter Sales 2006 Release - Tuesday, 17th October, 2006
more

19. September 2006
Once monthly oral Bonviva continues to be highly effective and well tolerated in the long-term treatment of osteoporosis
more

11. September 2006
Genentech receives complete response letter from FDA for Avastin in metastatic breast cancer
more

06. September 2006
Reminder: Invitation to Roche Diabetes Care Event during EASD Annual Meeting
more

01. September 2006
International Trade Commission rules in Roche's favour - Mircera case terminated
more

28. August 2006
Genentech and Biogene Idec announced positive results from a phase II trial of Rituxan in relapsing-remitting multiple sclerosis
more

09. August 2006
Invitation to Roche Diabetes Care Event during EASD Annual Meeting
more

08. August 2006
Avastin filed in Europe for treatment of most common form of lung cancer
more

31. July 2006
Full reconciliation of Chugai interim results into IFRS
more

31. July 2006
Avastin and Xeloda meet primary endpoints in large Phase III first line metastatic colorectal cancer study
more

28. July 2006
In the interests of patients, Roche will consider all options following CHMP opinion on Tarceva in pancreatic cancer
more

21. July 2006
Xeloda filed in Europe for treatment of advanced stomach cancer
more

20. July 2006
Roche in the first half of 2006: Outstanding growth
more

19. July 2006
Reminder: Roche´s Half Year Results and Report for 2006
more

19. July 2006
Roche exercises its option to license Ipsen´s anti-diabetic medicine for type 2 diabetes
more

17. July 2006
Actelion and Roche enter into autoimmune disorder collaboration
more

17. July 2006
Mircera (C.E.R.A.) first drug to directly convert dialysis patients to once-monthly dosing schedule
more

11. July 2006
MabThera approved in Europe for maintenance therapy in patients with common form of lymphoma
more

11. July 2006
MabThera approved for use in rheumatoid arthritis in Europe
more

10. July 2006
Invitation to conference call on Roche C.E.R.A. data and results
more

10. July 2006
Avastin filed in Europe for first-line treatment of women with advanced breast cancer
more

06. July 2006
Roche re-launches Corporate Sustainability website
more

03. July 2006
FDA approves Lucentis for the treatment of wet age-related macular degeneration
more

27. June 2006
US Phase III study of Avastin in advanced pancreatic cancer does not meet primary endpoint
more

26. June 2006
Roche´s Half Year Results and Report for 2006
more

26. June 2006
U.S. FDA approval of boosted protease inhibitor enables potent new HIV drug combination with Fuzeon
more

22. June 2006
New evidence shows MabThera inhibits joint damage in patients with rheumatoid arthritis
more

21. June 2006
FDA approves Avastin in combination with chemotherapy for second-line metastatic colorectal cancer patients
more

20. June 2006
Invitation to conference call on Roche data and results at EULAR 2006, 23 June 2006
more

15. June 2006
Reminder - Invitation to the Roche Oncology Event
more

09. June 2006
More breast cancer patients to be saved as Herceptin is given green light by the National Institute for Health and Clinical Excellence (NICE)
more

07. June 2006
Roche Annual Report Survey 2006
more

06. June 2006
New study suggests combining breakthrough therapies Tarceva and Avastin may provide more hope for lung cancer patients
more

06. June 2006
New Xeloda combination allows patients with stomach cancer to live significantly longer
more

06. June 2006
Largest ever data set shows consistent benefits with Avastin when used in combination with different chemotherapy treatments
more

06. June 2006
New data show impressive survival benefit for Herceptin in early-stage HER2-positive breast cancer
more

02. June 2006
MabThera Receives Positive Opinion In Europe For Maintenance Therapy In Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
more

02. June 2006
MabThera recommended for approval in rheumatoid arthritis in Europe
more

31. May 2006
IAS changes 2006 and effects on the Roche Group results
more

30. May 2006
Roche ASCO planner
more

29. May 2006
Herceptin added to hormonal therapy prolongs progression-free survival for patients with advanced HER2-positive breast cancer
more

26. May 2006
Avastin filed with FDA in US for treatment of women with advanced breast cancer
more

24. May 2006
Herceptin approved in Europe for early use in HER2-positive breast cancer
more

23. May 2006
Recruitment to resume in AVANT international phase III trial in post-surgical adjuvant colon cancer
more

22. May 2006
Invitation to the Roche Oncology Event, Zurich, June 19
more

02. May 2006
Roche´s innovative oral polymerase inhibitor shows strong antiviral activity in chronic hepatitis C patients
more

02. May 2006
Chronic hepatitis B patients still in remission two years after treatment with Pegasys
more

02. May 2006
New Pegasys trial shows six months of treatment is optimal for achieving a cure in "easier-to-treat" hepatitis C patients
more

28. April 2006
Chugai submitted Actemra in rheumatoid arthritis and a severe form of juvenile arthritis for approval in Japan
more

28. April 2006
Herceptin receives positive opinion in Europe for early use in HER2-positive breast cancer
more

27. April 2006
Roche submits European marketing application for novel anaemia drug CERA
more

26. April 2006
Actemra dramatically improves symptoms of rheumatoid arthritis for patients who have had an inadequate response to MTX therapy
more

26. April 2006
Roche showed continued strong sales growth in the first quarter 2006 - sales up by 15%
more

25. April 2006
Reminder: Roches First Quarter Sales 2006 Release
more

21. April 2006
Chugai files innovative cancer medicine Avastin for fast approval in Japan
more

20. April 2006
Roche submits application to FDA to market CERA for the treatment of renal anaemia
more

18. April 2006
Chugai files NDA for Tarceva in advanced or recurrent non-small cell lung cancer
more

12. April 2006
Avastin filed in US for the treatment of non-squamous, non-small cell lung cancer
more

06. April 2006
Oral chemotherapy Xeloda shown to be effective in gastric cancer
more

31. March 2006
New Bonviva Quarterly Injection Approved in Europe for Postmenopausal Osteoporosis
more

28. March 2006
Roche Oncology Event
more

27. March 2006
Roche´s First Quarter Sales 2006 Release
more

07. March 2006
New test for improved detection of HIV and hepatitis viruses in donated blood receives CE Mark certification
more

01. March 2006
FDA Approves First Rheumatoid Arthritis Indication for Rituxan (MabThera)
more

27. February 2006
Roche raises dividend by 25 percent
more

22. February 2006
NICE approves Pegasys for the first-line treatment of chronic hepatitis B
more

17. February 2006
Roche files Herceptin for early-stage HER2-positive breast cancer with European Authorities
more

15. February 2006
Genentech submits supplemental biologics license application for adjuvant Herceptin in early-stage HER2-positive breast cancer
more

13. February 2006
Recruitment temporarily suspended in an international phase III trial (AVANT) in post-surgical adjuvant colon cancer
more

09. February 2006
Full reconciliation of Chugai results into IFRS
more

01. February 2006
Roche 2005: Record sales and operating profit
more

31. January 2006
Reminder - Roche´s Full Year Results and Report for 2005
more

31. January 2006
Tamiflu gains approval in Europe for prevention of influenza in children aged 1 to 12 years
more

27. January 2006
European positive opinion for first quarterly I.V. injection for postmenopausal osteoporosis
more

24. January 2006
US FDA joint advisory committee recommends approval of weight loss drug Orlistat 60mg capsules for over the counter use
more

12. January 2006
Roche´s rapid sepsis test now available in the European Union
more

09. January 2006
Roche´s Full Year Results and Report for 2005
more

09. January 2006
FDA approves first quarterly I.V. injection for postmenopausal osteoporosis in US
more